20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Entera Bio Ltd (ENTX) operates in the BIOTECHNOLOGY industry and is headquartered in Jerusalem, Israel with about 20 employees. Its market capitalization is roughly $530 million. In the fiscal year ended 2025-12-31, ENTX reported $0M in revenue and ($11M) in net income.
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $1M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Margin % | — | -71.4% | 5.0% | -400.0% | 24.6% | 34.7% | 42.7% | -89.8% | 100.0% | — | — | — |
| Operating Income (EBIT) | ($14M) | ($12M) | ($10M) | ($9M) | ($13M) | ($12M) | ($11M) | ($11M) | ($11M) | $11M | ($5M) | ($4M) |
| Operating Margin % | — | -27450.0% | -5295.6% | -63857.1% | -9714.2% | -2139.6% | -3050.1% | -4853.4% | -2172.2% | — | — | — |
| Net Income | ($17M) | ($11M) | ($10M) | ($9M) | ($13M) | ($12M) | ($10M) | ($11M) | ($10M) | ($11M) | ($1M) | ($4M) |
| Net Margin % | — | -27235.7% | -5271.3% | -63492.9% | -9754.5% | -2134.3% | -2735.1% | -4574.2% | -2060.8% | — | — | — |
| EBITDA | ($14M) | ($11M) | ($9M) | ($9M) | ($13M) | ($12M) | ($11M) | ($10M) | ($11M) | ($11M) | ($5M) | ($4M) |
| Earnings Per Share (EPS) | $-0.35 | $-0.25 | $-0.25 | $-0.31 | $-0.45 | $-0.47 | $-0.54 | $-0.89 | $-0.90 | $-0.94 | $-0.10 | $-0.36 |
| Shares Outstanding (M) | 50M | 46M | 38M | 29M | 29M | 26M | 18M | 12M | 12M | 12M | 12M | 12M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | 0.0% | 0.0% | 0.0% |
| Operating Income (EBIT) | ($5M) | ($4M) | ($3M) | ($3M) | ($3M) | ($3M) | ($2M) | ($3M) |
| Operating Margin % | — | — | — | — | — | -6102.4% | -2850.0% | -7192.9% |
| Net Income | ($7M) | ($4M) | ($3M) | ($3M) | ($3M) | ($3M) | ($2M) | ($3M) |
| Net Margin % | — | — | — | — | — | -6111.9% | -2875.6% | -7192.9% |
| EBITDA | ($5M) | ($3M) | ($3M) | ($3M) | ($3M) | ($3M) | ($2M) | ($3M) |
| Earnings Per Share (EPS) | $-0.14 | $-0.07 | $-0.07 | $-0.07 | $-0.06 | $-0.06 | $-0.06 | $-0.08 |
| Shares Outstanding (M) | 50M | 48M | 46M | 47M | 47M | 43M | 38M | 38M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($11M) | ($7M) | ($7M) | ($7M) | ($12M) | ($9M) | ($11M) | ($9M) | ($10M) | ($5M) | ($3M) | ($3M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($11M) | ($7M) | ($7M) | ($7M) | ($13M) | ($9M) | ($11M) | ($9M) | ($10M) | ($5M) | ($3M) | ($4M) |
| FCF Margin % | — | -17802.4% | -3768.5% | -52335.7% | -9362.7% | -1590.2% | -2906.8% | -3796.2% | -1972.8% | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($3M) | ($3M) | ($2M) | ($3M) | ($2M) | ($1M) | ($1M) | ($2M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($3M) | ($3M) | ($2M) | ($3M) | ($2M) | ($1M) | ($1M) | ($2M) |
| FCF Margin % | — | — | — | — | — | -3361.9% | -1792.7% | -5128.6% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $19M | $16M | $9M | $12M | $13M | $26M | $10M | $17M | $13M | $13M | $6M | $3M |
| Cash & Cash Equivalents | $11M | $7M | $9M | $11M | $12M | $25M | $9M | $15M | $8M | $12M | $4M | $1M |
| Total Liabilities | $12M | $3M | $1M | $1M | $1M | $3M | $2M | $5M | $3M | $45M | $32M | $28M |
| Total Debt (Short + Long-Term) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $41M | $15M | $42M |
| Total Shareholders' Equity | $7M | $13M | $8M | $10M | $12M | $23M | $8M | $12M | $10M | ($32M) | ($25M) | ($26M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ENTX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms